Back to the drawing board

Re-thinking the role of GLI1 in pancreatic carcinogenesis

Martin E Fernandez-Zapico, Tara Hogenson, Matthias Lauth, Marina Pasca diMagliano

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aberrant activation of the transcription factor GLI1, a central effector of the Hedgehog (HH) pathway, is associated with several malignancies, including pancreatic ductal adenocarcinoma (PDAC), one of most deadly human cancers. GLI1 has been described as an oncogene in PDAC, making it a promising target for drug therapy. Surprisingly, clinical trials targeting HH/GLI1 axis in advanced PDAC were unsuccessful, leaving investigators questioning the mechanism behind these failures. Recent evidence suggests the loss of GLI1 in the later stages of PDAC may actually accelerate disease. This indicates GLI1 may play a dual role in PDAC, acting as an oncogene in the early stages of disease and a tumor-suppressor in the late stages.

Original languageEnglish (US)
JournalF1000Research
Volume3
DOIs
StatePublished - Oct 8 2014

Fingerprint

Carcinogenesis
Adenocarcinoma
Drug therapy
Tumors
Transcription Factors
Oncogenes
Chemical activation
Neoplasms
Research Personnel
Clinical Trials
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Back to the drawing board : Re-thinking the role of GLI1 in pancreatic carcinogenesis. / Fernandez-Zapico, Martin E; Hogenson, Tara; Lauth, Matthias; Pasca diMagliano, Marina.

In: F1000Research, Vol. 3, 08.10.2014.

Research output: Contribution to journalArticle

Fernandez-Zapico, Martin E ; Hogenson, Tara ; Lauth, Matthias ; Pasca diMagliano, Marina. / Back to the drawing board : Re-thinking the role of GLI1 in pancreatic carcinogenesis. In: F1000Research. 2014 ; Vol. 3.
@article{79907c1598194e688dba7bdd512d9310,
title = "Back to the drawing board: Re-thinking the role of GLI1 in pancreatic carcinogenesis",
abstract = "Aberrant activation of the transcription factor GLI1, a central effector of the Hedgehog (HH) pathway, is associated with several malignancies, including pancreatic ductal adenocarcinoma (PDAC), one of most deadly human cancers. GLI1 has been described as an oncogene in PDAC, making it a promising target for drug therapy. Surprisingly, clinical trials targeting HH/GLI1 axis in advanced PDAC were unsuccessful, leaving investigators questioning the mechanism behind these failures. Recent evidence suggests the loss of GLI1 in the later stages of PDAC may actually accelerate disease. This indicates GLI1 may play a dual role in PDAC, acting as an oncogene in the early stages of disease and a tumor-suppressor in the late stages.",
author = "Fernandez-Zapico, {Martin E} and Tara Hogenson and Matthias Lauth and {Pasca diMagliano}, Marina",
year = "2014",
month = "10",
day = "8",
doi = "10.12688/f1000research.5324.1",
language = "English (US)",
volume = "3",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Back to the drawing board

T2 - Re-thinking the role of GLI1 in pancreatic carcinogenesis

AU - Fernandez-Zapico, Martin E

AU - Hogenson, Tara

AU - Lauth, Matthias

AU - Pasca diMagliano, Marina

PY - 2014/10/8

Y1 - 2014/10/8

N2 - Aberrant activation of the transcription factor GLI1, a central effector of the Hedgehog (HH) pathway, is associated with several malignancies, including pancreatic ductal adenocarcinoma (PDAC), one of most deadly human cancers. GLI1 has been described as an oncogene in PDAC, making it a promising target for drug therapy. Surprisingly, clinical trials targeting HH/GLI1 axis in advanced PDAC were unsuccessful, leaving investigators questioning the mechanism behind these failures. Recent evidence suggests the loss of GLI1 in the later stages of PDAC may actually accelerate disease. This indicates GLI1 may play a dual role in PDAC, acting as an oncogene in the early stages of disease and a tumor-suppressor in the late stages.

AB - Aberrant activation of the transcription factor GLI1, a central effector of the Hedgehog (HH) pathway, is associated with several malignancies, including pancreatic ductal adenocarcinoma (PDAC), one of most deadly human cancers. GLI1 has been described as an oncogene in PDAC, making it a promising target for drug therapy. Surprisingly, clinical trials targeting HH/GLI1 axis in advanced PDAC were unsuccessful, leaving investigators questioning the mechanism behind these failures. Recent evidence suggests the loss of GLI1 in the later stages of PDAC may actually accelerate disease. This indicates GLI1 may play a dual role in PDAC, acting as an oncogene in the early stages of disease and a tumor-suppressor in the late stages.

UR - http://www.scopus.com/inward/record.url?scp=84923197451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923197451&partnerID=8YFLogxK

U2 - 10.12688/f1000research.5324.1

DO - 10.12688/f1000research.5324.1

M3 - Article

VL - 3

JO - F1000Research

JF - F1000Research

SN - 2046-1402

ER -